Otc - Active Ingredient
Active Ingredient
Salicylic Acid
Two percent
Acne Control Body Wash
FDA Label NDC 76348-441
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Renu Laboratories Inc. for the product Acne Control Body Wash (NDC 76348-441). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding otc - active ingredient, otc - keep out of reach of children, purpose, questions, warnings, use:, dosage & administration, recent major changes, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Otc - Keep Out Of Reach Of Children
Keep out of reach of children. If swallowed, contact physician or poison control center immediately.
Purpose
Acne Treatment
Questions
Call 844 425 4948
Made in the USA
Distributed by Clixit, LLC Orlando, FL
Warnings
Warnings
For external use only Using other topical acne medications at the same time may increase dryness or irritation of the skin
If bothersome dryness or irritation occurs use only one medication unless directed by doctor
Use:
For the treatment of acne.
Dosage & Administration
Directions
Use daily in shower or bath
For maximum lather massage over wet skin with a washcloth sponge or body puff concentrating on areas of the body prone to breakout
Rinse well
Recent Major Changes
Punctuation marks changed only
9/2019
Other Ingredients:
Acrylates Copolymer, Aloe Barbadensis, Cannabis Sativa (Hemp) Seed Oil, Capryl Glycol, Chamomilla Recutita (Matricaria) Flower Extract, Citric Acid, Cocamidopropyl Betaine, Deionized Water, Ethylhexylglycerin, Glycerin, Glycolic Acid, Hexylene Glycol, Phenoxyethanol, Sodium C14-16 Olefin Sulfonate, Sodium Hydroxide, Tocopherol.
Package Label.Principal Display Panel
* Please review the disclaimer below.
